missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Aprutumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
Marke: Invitrogen™ MA558315
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Aprutumab is a biosimilar that targets FGFR2. FGFR2 is a member of the fibroblast growth factor receptor family. It is a tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a central role in the regulation of cell proliferation, differentiation, migration, apoptosis, and embryonic development. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene.
Spezifikation
| Aprutumab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| BAY 1179470 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur